Table 4

Correlations between clinical eligibility criteria, national indicators of socioeconomic development and health status indicators of patients with RA in 36 countries of the European Region (27 countries of the European Union)*

Clinical eligibility criteriaIndicators of socioeconomic welfareHealth status indicators of patients with RAUptake of bDMARDs
GDP per capita (int.$) n=27–36†Median income (int.$) n=27–30†Total health expenditure per capita (int.$) n=27–36†DAS28 n=17–20†TJC n=17–20†MD Global VAS n=17–20†HAQ n=17–20†PT global VAS n=17–20†ESR n=17–20†bDMARDs ever, % of patients n=16–18†
Minimum disease duration (months)−0.41 (−0.48)−0.50 (−0.45)−0.34 (−0.4)0.48 (0.37)0.47 (0.33)0.48 (0.38)0.51 (0.42)0.33 (0.24)0.33 (0.32)−0.58 (−0.60)
Level of DAS28−0.61 (−0.49)−0.60 (−0.55)−0.64 (−0.56)0.36 (0.29)0.26 (0.25)0.36 (0.35)0.41 (0.36)0.27 (0.24)0.40 (0.33)−0.31 (−0.21)
Number of sDMARDs to be failed−0.56 (−0.47)−0.46 (−0.37)−0.54 (−0.41)0.17 (0.13)0.19 (0.22)0.18 (0.21)0.23 (0.19)0.11 (0.05)0.28 (0.15)−0.70 (−0.68)
Composite score for clinical eligibility criteria (0–5)0.70 (0.63)0.67 (0.59)0.72 (0.66)−0.46 (−0.39)−0.42 (−0.42)−0.45 (−0.46)−0.52 (−0.46)−0.33 (−0.27)−0.48 (−0.40)0.79 (0.72)
  • *First value corresponds to Spearman correlation between both variables in all the 36 countries and the second value refers to the same correlation but within those countries that are from the European Union.

  • †n corresponds to the minimum and maximum number of countries from which there were data for each of the correlations.

  • bDMARD, biologic disease-modifying antirheumatic drug; DAS28, disease activity score with 28-joint assessment; ESR, erythrocyte sedimentation rate; GDP, gross domestic product; HAQ, Health Assessment Questionnaire; MD, medical doctor; PT, patient; RA, rheumatoid arthritis; sDMARDs, synthetic disease-modifying antirheumatic drugs; TJC, tender joint count; VAS, Visual Analogue Scale.